Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Remab Therapeutics Sl’s profile records 1 pending office action in Biotechnology & Pharmaceuticals. The matter is associated with 1 distinct examiner and 1 distinct art unit. VU, JAKE MINH is the busiest examiner, with 1 pending matter. The available figures show a concentrated prosecution record for the company’s biotechnology and pharmaceutical subject matter.
For counsel, the pending action should be handled as the principal prosecution event in the profile. The response can be aligned to the cited examiner’s reasoning and the assigned art-unit practice, with claim amendments supported by the application disclosure. Because the record does not show multiple examination assignments, consistency between the response, the claim set, and the existing prosecution history should be straightforward to maintain.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| VU, JAKE MINH | 1 | 41.0% | +27.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18025165 | GLYCOCONJUGATES AND MEDICAL USES THEREOF | VU, JAKE MINH | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18025165 | GLYCOCONJUGATES AND MEDICAL USES THEREOF | VU, JAKE MINH | — |
| Art Unit | Apps |
|---|---|
| 1618 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18025165 | GLYCOCONJUGATES AND MEDICAL USES THEREOF | VU, JAKE MINH | 1618 | §103§112 | Final Rejection | — | Pending | Mar 07, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialRemab Therapeutics Sl has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Jake Minh Vu has the most, with 1 of Remab Therapeutics Sl's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
